Cargando…

New Horizons: Artificial Intelligence Tools for Managing Osteoporosis

Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration leading to increased bone fragility and fracture risk. Typically, osteoporotic fractures occur at the spine, hip, distal forearm, and proximal humerus, but other skeletal sites may be affected as well. One...

Descripción completa

Detalles Bibliográficos
Autor principal: Dimai, Hans Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999362/
https://www.ncbi.nlm.nih.gov/pubmed/36477337
http://dx.doi.org/10.1210/clinem/dgac702
_version_ 1784903649411989504
author Dimai, Hans Peter
author_facet Dimai, Hans Peter
author_sort Dimai, Hans Peter
collection PubMed
description Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration leading to increased bone fragility and fracture risk. Typically, osteoporotic fractures occur at the spine, hip, distal forearm, and proximal humerus, but other skeletal sites may be affected as well. One of the major challenges in the management of osteoporosis lies in the fact that although the operational diagnosis is based on bone mineral density (BMD) as measured by dual x-ray absorptiometry, the majority of fractures occur at nonosteoporotic BMD values. Furthermore, osteoporosis often remains undiagnosed regardless of the low severity of the underlying trauma. Also, there is only weak consensus among the major guidelines worldwide, when to treat, whom to treat, and which drug to use. Against this background, increasing efforts have been undertaken in the past few years by artificial intelligence (AI) developers to support and improve the management of this disease. The performance of many of these newly developed AI algorithms have been shown to be at least comparable to that of physician experts, or even superior. However, even if study results appear promising at a first glance, they should always be interpreted with caution. Use of inadequate reference standards or selection of variables that are of little or no value in clinical practice are limitations not infrequently found. Consequently, there is a clear need for high-quality clinical research in this field of AI. This could, eg, be achieved by establishing an internationally consented “best practice framework” that considers all relevant stakeholders.
format Online
Article
Text
id pubmed-9999362
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-99993622023-03-11 New Horizons: Artificial Intelligence Tools for Managing Osteoporosis Dimai, Hans Peter J Clin Endocrinol Metab Mini-Review Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration leading to increased bone fragility and fracture risk. Typically, osteoporotic fractures occur at the spine, hip, distal forearm, and proximal humerus, but other skeletal sites may be affected as well. One of the major challenges in the management of osteoporosis lies in the fact that although the operational diagnosis is based on bone mineral density (BMD) as measured by dual x-ray absorptiometry, the majority of fractures occur at nonosteoporotic BMD values. Furthermore, osteoporosis often remains undiagnosed regardless of the low severity of the underlying trauma. Also, there is only weak consensus among the major guidelines worldwide, when to treat, whom to treat, and which drug to use. Against this background, increasing efforts have been undertaken in the past few years by artificial intelligence (AI) developers to support and improve the management of this disease. The performance of many of these newly developed AI algorithms have been shown to be at least comparable to that of physician experts, or even superior. However, even if study results appear promising at a first glance, they should always be interpreted with caution. Use of inadequate reference standards or selection of variables that are of little or no value in clinical practice are limitations not infrequently found. Consequently, there is a clear need for high-quality clinical research in this field of AI. This could, eg, be achieved by establishing an internationally consented “best practice framework” that considers all relevant stakeholders. Oxford University Press 2022-12-08 /pmc/articles/PMC9999362/ /pubmed/36477337 http://dx.doi.org/10.1210/clinem/dgac702 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Mini-Review
Dimai, Hans Peter
New Horizons: Artificial Intelligence Tools for Managing Osteoporosis
title New Horizons: Artificial Intelligence Tools for Managing Osteoporosis
title_full New Horizons: Artificial Intelligence Tools for Managing Osteoporosis
title_fullStr New Horizons: Artificial Intelligence Tools for Managing Osteoporosis
title_full_unstemmed New Horizons: Artificial Intelligence Tools for Managing Osteoporosis
title_short New Horizons: Artificial Intelligence Tools for Managing Osteoporosis
title_sort new horizons: artificial intelligence tools for managing osteoporosis
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999362/
https://www.ncbi.nlm.nih.gov/pubmed/36477337
http://dx.doi.org/10.1210/clinem/dgac702
work_keys_str_mv AT dimaihanspeter newhorizonsartificialintelligencetoolsformanagingosteoporosis